Amarin investors nervous over FDA Vascepa review; shares tumble
This article was originally published in Scrip
Executive Summary
Because of the shutdown of most of the US government, investors likely already were feeling a bit edgy on 11 October after waiting longer than usual for the US FDA to release briefing documents revealing drug reviewers' thinking about whether Amarin should be permitted to substantially expand the treatment population for the firm's fish oil pill Vascepa (AMR101).